Abstract
Precision medicine is shaping the way medicine is being practiced, pharmacogenomics is the centerpiece of precision medicine. As in several fields, researchers are investigating the role of pharmacogenomic tests in the treatment of melanoma. One of these efforts is the ongoing preclinical and clinical trials investigating the impact of the genetic polymorphism of cytotoxic T-lymphocyte antigen-4 on drugs used in melanoma treatment. This paper reviews ipilimumab as a promising treatment for melanoma and how pharmacogenomic tests can substantially impact utilizing this drug in the treatment plan, whether as a solo treatment or in conjugation with other therapies. In this review, various databases and electronic libraries were utilized to search for and review different journal articles and papers about pharmacogenomic tests for ipilimumab. Although some results showed a minimal effect, most of the results revealed that pharmacogenomic tests for ipilimumab could play a crucial role in patients’ outcomes. Further clinical trials are, however, needed on a larger scale to adopt this therapy in practice.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
